Albany, New York 12208


This randomized, double-blind, placebo-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV ATYR1923 in patients with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to ATYR1923 (N=8) or placebo (N=4).


Key Inclusion Criteria: - Diagnosis of pulmonary sarcoidosis for ≥1 year (cutaneous and ocular involvement allowed), defined as: - Histologically proven diagnosis of sarcoidosis by biopsy or bronchioalveolar lavage - Parenchymal lung involvement by historical radiological evidence - Must have symptomatic and/or active pulmonary sarcoidosis as evidence by: - Modified Medical Research Council Dyspnea Scale grade of >= 1; and - Forced vital capacity ≥50 and ≤90 percent predicted; and - Positive 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG-PET/CT) scan showing increased metabolic activity in lung parenchyma within 4 weeks prior to Day 1. - Receiving treatment with 10 to 25 mg/day of oral prednisone (or equivalent), at a stable dose for ≥4 weeks prior to Day 1, and capable of undergoing the protocol-specified steroid taper regimen. - Body weight ≥55 kg and <140 kg. Key Exclusion Criteria: - Current disease presentation consistent with Lofgren's syndrome. - History of severe allergic or anaphylactic reactions to therapeutic proteins. - Treatment with biological immunomodulators such as tumor necrosis factor-alpha inhibitors. - Current evidence of clinically significant cardiovascular, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires other treatment. - Clinically significant pulmonary hypertension requiring vasodilator treatment. - History or evidence of active or latent systemic fungal or mycobacterial infection. - History of clinically significant cardiac, neurological, gastrointestinal, and/or renal manifestations of their sarcoidosis. - Any condition that necessitated hospitalization within the 3 months prior to Day 1 or is likely to require so during the study. - Participation in another clinical study of an investigational agent or device within 3 months (small molecules) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer. - History of or positive results of screening for hepatitis B, hepatitis C or human immunodeficiency virus. - Has smoked or inhaled (including e-cigarettes or e-vaporizers) any nicotine containing product within 6 months prior to Screening. - Active substance abuse or history of substance abuse within the 12 months prior to Screening. - Patient has received a live vaccination within 8 weeks before Day 1 or inoculation with a live vaccine is planned during study participation. - Positive for Jo-1 antibodies (Ab) at Screening, or past history of Jo-1 Ab positivity. - Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator.



Primary Contact:

Study Director
Gennyne Walker
aTyr Pharma, Inc.

aTyr Pharma Clinical Research
Phone: 877-215-5731

Backup Contact:


Location Contact:

Albany, New York 12208
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.